Search
Fluocinolone acetonide
go.drugbank.com/drugs/DB00591ApprovedInvestigationalVet approved[T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices. … [T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]
Mixtures: OCIDERM-N, CINOLON-NIroxanadine
go.drugbank.com/drugs/DB05444ExperimentalIt induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). … EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease).
Lifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigationalLifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341 … ] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.
Peramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalPeramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells.
Succinylcholine
go.drugbank.com/drugs/DB00202ApprovedInvestigational[A19054] It has been widely used for over 50 years,[A299] most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. … Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short
Synonyms: 2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)Products: Suxamethonium Aguettant 10 mg/ml Injektionslösung in einer FertigspritzeClobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974. … [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Mixtures: FOLISTER COMPLEX HAIR LOTION (R), FOLISTER COMPLEX HAIR LOTION (R)Synonyms: Clobetasol propionate EFactor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalCompared to Factor XIII (human), which is purified from pooled human plasma, [DB09310] is produced through recombinant DNA technology where the target protein is grown in yeast and then isolated [FDA Label … Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation
Minocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigationalMinocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. … [A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]
Umeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalANORO ELLIPTA was approved in December 2013 while TRELEGY ELLIPTA was approved in September 2017.[L46881,L46886] … [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]